News | March 16, 2026
C2N Diagnostics expands Alzheimer’s blood test to South Korea via BeauBrain partnership
Under the agreement, healthcare professionals in the country will gain access to C2N’s PrecivityAD2 blood test
Under the agreement, healthcare professionals in the country will gain access to C2N’s PrecivityAD2 blood test
Previously, Arexvy was authorized for adults 60 and older, and for those 50–59 with heightened risk
This study demonstrates the power of real-time glucose information for people with Type 2 diabetes treated with basal insulin
The expanded ownership is expected to improve access to Cialis for millions of men in Asia affected by ED and BPH
There are limited treatment options available for patients living with non-diabetic CKD, and the unmet need is high for new treatments to delay kidney disease progression and reduce cardiovascular risk
The facility will manufacture the critical antibiotic intermediate Amino Cephalosporanic Acid (ACA), a key component in the production of cephalosporin antibiotics
The initiative will focus on creating healthier early-life environments, promoting physical activity, identifying risks early, and strengthening preparedness within primary health care systems
The new entity will operate with separate resources, funding, and operations, while BioNTech will contribute related rights and mRNA technologies to support its ambitious mission
Neupharma gains exclusive rights to develop and commercialize corticorelin for peritumoral brain edema
The trial’s primary goal is to evaluate vipoglanstat’s effect on endometriosis-related pain during non-menstrual days
Subscribe To Our Newsletter & Stay Updated
